Biogen, Novo lead new class of hemophilia drugs; Biotech veteran Zaffaroni dead at 91;

@FierceBiotech: After 2 years trailing Boston, San Francisco rules our list of the top 15 cities for biotech VC. Report | Follow @FierceBiotech

@JohnCFierce: And continuing to run strong from Wednesday, which is unusual--FDA rejects Eli Lilly's SGLT2 diabetes drug empagliflozin. Story | Follow @JohnCFierce

@DamianFierce: NewLink's cancer vaccine brings hopeful investors back down to earth. More | Follow @DamianFierce

@EmilyMFierce: Stem cell therapy developed by International Stem Cell Corp. improves Parkinsons symptoms in monkeys. Story | Follow @EmilyMFierce

> Led by Biogen Idec ($BIIB) and Novo Nordisk ($NVO), a new generation of hemophilia B treatments promise to improve patients' lives. Story

> After helping to found Alza, Affymetrix ($AFFX), Alexza Pharmaceuticals ($ALXA) and others, storied biotech veteran Alejandro Zaffaroni has died at 91. Article

> Sales of Gilead Sciences' ($GILD) hepatitis C drug Sovaldi have already outstripped analyst expectations. News

Medical Device News

@FierceMedDev: Quotient, a UK diagnostics outfit, filed plans for a $75M IPO. Via Renaissance Capital. Brief | Follow @FierceMedDev

@MarkHFierce: The European Patent Office tossed out an Edwards heart valve patent--a big victory for rival Medtronic. More | Follow @MarkHFierce

@MichaelGFierce: Study: In two-drug, HIV-preventing vaginal ring, only one drug does the job. Piece | Follow @MichaelGFierce

@EmilyWFierce: Stapler-sized device could identify disease biomarkers and insulin levels, all in one read. Story via RTT News | Follow @EmilyWFierce

@GalenMoore: Last year's M&A darling, Biomet files for an IPO. It's said to be looking for a $1B raise. News | Follow @GalenMoore

> AngioDynamics plans late FY14 rollout for latest dialysis catheter. Story

> Vermillion reports Q4 earnings fueled by its ovarian cancer diagnostic. Article

Pharma News

@FiercePharma: And the best-read special report, our newest: The top 10 pharma companies by 2013 revenue. Report | Follow @FiercePharma

@TracyStaton: ICYMI: It's trial by fire for Zogenix, as painkiller Zohydro's launch meets public furor. News | Follow @TracyStaton

@EricPFierce: Novartis has more skin in the dermatology game with EU approval of Xolair to treat chronic hives. Story | Follow @EricPFierce

@CarlyHFierce: Working on a new report... looks like it's time to add "write extensive Advair pieces off the top of my head" to my list of party tricks. | Follow @CarlyHFierce

> Pfizer recalls 104,000 bottles of antidepressant Effexor XR. Story

> Gilead's Sovaldi sales through the roof already, analyst predicts at least $8B this year. Article

Suggested Articles

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.

VistaGen responded to the failure of the ketamine-line drug by vowing to review all the data before deciding on next steps.

Exicure is set to receive $25 million upfront to apply its spherical nucleic acid technology to two collaborative programs.